News: Celgene Corp (CELG.O)

CELG.O on Nasdaq

109.90USD
4 May 2015
Change (% chg)

-- (--)
Prev Close
$109.90
Open
--
Day's High
--
Day's Low
--
Volume
100
Avg. Vol
5,612,089
52-wk High
$129.06
52-wk Low
$71.32

Search Stocks
Select another date:

Thu, Apr 30 2015

US STOCKS-Wall St drops with tech shares; LinkedIn falls late

* Indexes down: Dow 1.1 pct, S&P 1 pct, Nasdaq 1.6 pct (Updates close with LinkedIn, solar company shares down after the bell, Gilead up, small caps down, new quote)

US STOCKS-Wall St drops with tech shares; indexes up for month

* Indexes down: Dow 1.1 pct, S&P 1 pct, Nasdaq 1.6 pct (Updates to close)

Celgene sales highlight Revlimid dependence ahead of patent ruling

- Celgene Corp's dependence on its big-selling multiple myeloma drug Revlimid raised investor concerns on Thursday as sales of its other medicines fell short of expectations.

Celgene sales highlight Revlimid dependence ahead of patent ruling

April 30 - Celgene Corp's dependence on its big-selling multiple myeloma drug Revlimid raised investor concerns on Thursday as sales of its other medicines fell short of expectations.

US STOCKS-Wall St drops with tech shares; Nasdaq down for 4th day

* Indexes down: Dow 1.4 pct, S&P 1.3 pct, Nasdaq 1.9 pct (Updates to late afternoon)

US STOCKS-Wall St falls on mixed economic data; Apple weighs

* Indexes down: Dow 0.6 pct, S&P 0.6 pct, Nasdaq 1 pct (Updates to early afternoon)

US STOCKS-Wall St falls on mixed economic data; Apple weighs

* Indexes down: Dow 0.5 pct, S&P 0.5 pct, Nasdaq 0.9 pct (Changes comment, updates prices)

Celgene revenue rises less than expected due to strong dollar

- U.S. biotechnology company Celgene Corp posted a lower-than-expected quarterly revenue, hit by a stronger dollar, but said the dollar would not hurt full-year sales and profit more that it had already forecast.

US STOCKS-Wall St opens lower as Apple, Celgene weigh

* Indexes down: Dow 0.7 pct, S&P 0.7 pct, Nasdaq 1 pct (Updates to open)

BRIEF-Celgene sees 2015 Revlimid sales at or above high end of forecast range

* Says now expects 2015 Revlimid sales at or above upper end of forecast range of $5.6 billion to $5.7 billion Further company coverage: (Reporting By Bill Berkrot)

Select another date:
Search Stocks